KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Deferred Taxes (2021 - 2025)

Historic Deferred Taxes for Halozyme Therapeutics (HALO) over the last 9 years, with Q4 2025 value amounting to $16.8 million.

  • Halozyme Therapeutics' Deferred Taxes rose 965.21% to $16.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$634000.0, marking a year-over-year decrease of 1917.29%. This contributed to the annual value of -$634000.0 for FY2025, which is 1917.29% down from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Deferred Taxes is $16.8 million, which was up 965.21% from -$27.4 million recorded in Q3 2025.
  • Halozyme Therapeutics' Deferred Taxes' 5-year high stood at $142.5 million during Q3 2021, with a 5-year trough of -$27.4 million in Q3 2025.
  • Its 5-year average for Deferred Taxes is $4.4 million, with a median of -$2.6 million in 2023.
  • Data for Halozyme Therapeutics' Deferred Taxes shows a peak YoY increase of 32137.88% (in 2025) and a maximum YoY decrease of 926780.82% (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Deferred Taxes stood at $13.0 million in 2021, then tumbled by 213.3% to -$14.7 million in 2022, then soared by 35.79% to -$9.4 million in 2023, then soared by 262.28% to $15.3 million in 2024, then rose by 9.65% to $16.8 million in 2025.
  • Its Deferred Taxes was $16.8 million in Q4 2025, compared to -$27.4 million in Q3 2025 and $7.1 million in Q2 2025.